MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants.

MAIA Biotechnology has commenced an underwritten public offering of common stock and pre-funded warrants. The offering will be offered by the company, with an option to purchase additional shares. The proposed offering is subject to market and other conditions. The offering is intended to raise capital to support the company's clinical-stage biopharmaceutical development for cancer treatments.